The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; Regeneron; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Fiona C. Thistlethwaite
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Biosciences; GlaxoSmithKline
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); Kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Other Relationship - iMatch Lead
 
Alexander I. Spira
Honoraria - AstraZeneca/MedImmune; CytomX Therapeutics; Merck
Consulting or Advisory Role - Array BioPharma (Inst)
Research Funding - Abbvie (Inst); Archer (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Javier Garcia-Corbacho
No Relationships to Disclose
 
Manreet Randhawa
No Relationships to Disclose
 
Ferry Eskens
Consulting or Advisory Role - Eisai; Ipsen; Merck Serono; Roche
Travel, Accommodations, Expenses - Pfizer
 
Bert O'Neil
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; Merck
Speakers' Bureau - Celgene
Travel, Accommodations, Expenses - Bayer; Merck KGaA
 
Javier Lavernia
No Relationships to Disclose
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group; LEK; Lilly; M3
Research Funding - EMD Serono (Inst); Taiho Pharmaceutical (Inst)
 
Omid Hamid
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Roche
Speakers' Bureau - Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Novartis; Sanofi/Regeneron
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); NextCure (Inst); Novartis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pfizer (Inst); Polynoma (Inst); Regeneron (Inst); Roche (Inst)
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
Beverly A. Benson
Employment - CytomX Therapeutics
 
William Garner
Employment - CytomX Therapeutics
 
Vanessa Jessica Huels
Employment - Abbvie (I); CytomX Therapeutics; Threshold Pharmaceuticals
Stock and Other Ownership Interests - Abbvie (I); CytomX Therapeutics; Threshold Pharmaceuticals
 
Hendrik-Tobias Arkenau
Employment - Hospital Corporation of America
Honoraria - BeiGene; Bicycle Therapeutics; Guardant Health; Merck KGaA; Roche; SERVIER
 
Patricia LoRusso
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; Chiltern; CytomX Therapeutics; Five Prime Therapeutics; Genentech; Genmab; Glenmark; Halozyme; Ignyta; Menarini; Novartis; Novella Clinical; Omniox; Roche/Genentech; Takeda
Research Funding - Alexion Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche